ImageneBio annual r&d spending
2020
2021
2022
2023
2024
2025
ImageneBio R&D Spending Growth & History (IMA)
ImageneBio's r&d spending was $28.5M for fiscal 2025.
View full ImageneBio company overviewImageneBio annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $28.5M | −$3.6M | −11.16% |
| 2024 | 2024-12-31 | $32.1M | −$27.5M | −46.17% |
| 2023 | 2023-12-31 | $59.7M | −$4.7M | −7.26% |
| 2022 | 2022-12-31 | $64.3M | $17.2M | +36.54% |
| 2021 | 2021-12-31 | $47.1M | $2.3M | +5.04% |
| 2020 | 2020-12-31 | $44.8M | — | — |
ImageneBio quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.7M | $1.0M | +17.97% |
| Q1 2026 | 2026-03-31 | $6.0M | $1.9M | +47.55% |
| Q4 2025 | 2025-12-31 | $3.3M | −$5.5M | −62.57% |
| Q3 2025 | 2025-09-30 | $15.6M | $11.7M | +300.46% |
| Q2 2025 | 2025-06-30 | $5.7M | −$4.2M | −42.50% |
| Q1 2025 | 2025-03-31 | $4.0M | −$5.6M | −58.11% |
| Q4 2024 | 2024-12-31 | $8.7M | −$5.5M | −38.72% |
| Q3 2024 | 2024-09-30 | $3.9M | −$10.8M | −73.49% |
| Q2 2024 | 2024-06-30 | $9.8M | −$5.3M | −35.20% |
| Q1 2024 | 2024-03-31 | $9.6M | −$5.9M | −37.98% |
| Q4 2023 | 2023-12-31 | $14.3M | −$1.4M | −8.73% |
| Q3 2023 | 2023-09-30 | $14.7M | −$4.2M | −22.26% |
| Q2 2023 | 2023-06-30 | $15.2M | −$316,000 | −2.04% |
| Q1 2023 | 2023-03-31 | $15.6M | $1.2M | +8.43% |
| Q4 2022 | 2022-12-31 | $15.6M | $3.3M | +26.76% |
| Q3 2022 | 2022-09-30 | $18.9M | $5.5M | +40.93% |
| Q2 2022 | 2022-06-30 | $15.5M | $4.1M | +36.17% |
| Q1 2022 | 2022-03-31 | $14.3M | $4.3M | +43.13% |
| Q4 2021 | 2021-12-31 | $12.3M | −$11.1M | −47.28% |
| Q3 2021 | 2021-09-30 | $13.4M | $6.2M | +85.30% |
| Q2 2021 | 2021-06-30 | $11.4M | $5.0M | +79.57% |
| Q1 2021 | 2021-03-31 | $10.0M | $2.1M | +26.96% |
| Q4 2020 | 2020-12-31 | $23.4M | — | — |
| Q3 2020 | 2020-09-30 | $7.2M | — | — |
| Q2 2020 | 2020-06-30 | $6.3M | — | — |
| Q1 2020 | 2020-03-31 | $7.9M | — | — |
ImageneBio r&d spending trends
Over the last five fiscal years, ImageneBio's r&d spending decreased from $44.8M to $28.5M, a change of −$16.3M. The latest reported quarter, Q2 2026, shows $6.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ImageneBio source filings ↗